Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is a commercial-stage biopharmaceutical company with a positive outlook due to its strong pipeline of precision medicines, including its AdenoVerse and UltraCAR-T platforms. The company's recent updates on its PRGN-2009 oncology asset and the early success of its Papzimeos launch have boosted investor confidence. With promising clinical data, market exclusivity, and potential label expansions, Precigen is poised for growth and has a current price target of $14 per share.

Bears say

Precigen is currently maintaining a Buy rating on PGEN with a 12-month price target of $14.00 per diluted share, derived from a risk-adjusted net present value analysis of projected future revenues from its lead product Papzimeos. However, this outlook is reliant on successful clinical, regulatory, commercial, partnership, financial, and intellectual property factors. Expansion opportunities for Papzimeos into pediatrics and redosing could provide incremental updates and investors expect positive Phase 2 data for PRGN-2009 by year-end, potentially extending the company's investment thesis in HPV-driven oncology markets.

Precigen (PGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Precigen (PGEN) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.